Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Time to wake up and smell the coffee? Coffee consumption and multiple sclerosis.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Covis Pharma to Acquire U.S. Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
Integrating Acupuncture Within a Wellness Intervention for Women With Multiple Sclerosis: A Feasibility Study.
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
Rituximab does not reset defective early B cell tolerance checkpoints.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
The endocannabinoid system and multiple sclerosis.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Pages
« first
‹ previous
…
23
24
25
26
27
28
29
30
31
…
next ›
last »